# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

> **NCT04216342** · PHASE1 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 64 (estimated)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **BIOLOGICAL:** Fx-5A peptide complex

## Key facts

- **NCT ID:** NCT04216342
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-29
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216342, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT04216342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*